ALK and lung carcinoma: Although genetic alterations in TP53, EGFR, EML4-ALK, PIK3CA, and KRAS have been identified as biomarkers of lung cancer, difficulties remain in diagnosing, predicting the prognosis of, and treating lung cancer patients.